Information Provided By:
Fly News Breaks for February 4, 2016
PACB
Feb 4, 2016 | 05:30 EDT
Piper Jaffray analyst William Quirk downgraded Pacific Biosciences to Neutral citing valuation following the company's Q4 results. Quick raised his price target for the shares to $11 from $9.